false Protagenic Therapeutics, Inc.new 0001022899 0001022899 2025-01-22 2025-01-22 0001022899 PTIX:ProtagenicTherapeuticsInc.CommonStockMember 2025-01-22 2025-01-22 0001022899 PTIX:ProtagenicTherapeuticsInc.CommonStockWarrantsMember 2025-01-22 2025-01-22 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

 

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of Earliest Event Reported): January 22, 2025

 

PROTAGENIC THERAPEUTICS, INC.

 

(Exact name of Company as specified in its charter)

 

Delaware   001-12555   06-1390025

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(I.R.S. Employer

Identification No.)

 

149 Fifth Avenue, Suite 500, New York, NY   10010
(Address of principal executive offices)   (Zip Code)

 

212-994-8200

 

(Company’s telephone number, including area code)

 

 

 

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Company under any of the following provisions:

 

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
   
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
   
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
   
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
         
Protagenic Therapeutics, Inc. Common Stock   PTIX   Nasdaq
Protagenic Therapeutics, Inc. Common Stock Warrants   PTIXW   Nasdaq

 

 

 

 

 

 

Item 3.01. Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

 

As previously reported, on July 24, 2024, Protagenic Therapeutics, Inc. (the “Company”) received a notification letter from the Nasdaq Listing Qualifications department (“Nasdaq”) indicating that, based upon the closing bid price of the Company’s common stock for the last 30 consecutive business days, the Company no longer met the requirement to maintain a minimum bid price of $1.00 per share, as set forth in Nasdaq Listing Rule 5550(a)(2) (“Rule 5550(a)(2)”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company was provided an initial period of 180 calendar days, or until January 21, 2025, to regain compliance.

 

On January 22, 2025, Nasdaq provided a notice to the Company that the Company had not regained compliance with Rule 5550(a)(2) and is not eligible for a second 180 calendar day compliance period as the Company does not comply with the requirements for initial listing on The Nasdaq Capital Market. This notification is part of the ongoing discussions with the Nasdaq Hearings Panel (the “Panel”) regarding the Company’s listing status, and the Company will include this matter in its presentation to the Panel on January 30, 2025.

 

Importantly, the notification letter has no immediate effect on the listing of the Company’s securities on the Nasdaq Capital Market, and the Company remains focused on meeting all listing requirements in the normal course of business.

 

2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  PROTAGENIC THERAPEUTICS, INC.
     
Date: January 29, 2025 By: /s/ Alexander K. Arrow
  Name: Alexander K. Arrow
  Title: Chief Financial Officer

 

3

 

v3.24.4
Cover
Jan. 22, 2025
Document Type 8-K
Amendment Flag false
Document Period End Date Jan. 22, 2025
Entity File Number 001-12555
Entity Registrant Name Protagenic Therapeutics, Inc.new
Entity Central Index Key 0001022899
Entity Tax Identification Number 06-1390025
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 149 Fifth Avenue
Entity Address, Address Line Two Suite 500
Entity Address, City or Town New York
Entity Address, State or Province NY
Entity Address, Postal Zip Code 10010
City Area Code 212
Local Phone Number 994-8200
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Protagenic Therapeutics, Inc. Common Stock  
Title of 12(b) Security Protagenic Therapeutics, Inc. Common Stock
Trading Symbol PTIX
Security Exchange Name NASDAQ
Protagenic Therapeutics, Inc. Common Stock Warrants  
Title of 12(b) Security Protagenic Therapeutics, Inc. Common Stock Warrants
Trading Symbol PTIXW
Security Exchange Name NASDAQ
Protagenic Therapeutics (NASDAQ:PTIXW)
Historical Stock Chart
From Jan 2025 to Feb 2025 Click Here for more Protagenic Therapeutics Charts.
Protagenic Therapeutics (NASDAQ:PTIXW)
Historical Stock Chart
From Feb 2024 to Feb 2025 Click Here for more Protagenic Therapeutics Charts.